"Arrr, me hearties! 'Tis a fine treasure map to victory in thee battle against the scurvy lung beasts!"
2024-06-01
Arr matey! The scallywags be talkin' 'bout how crizotinib may not be the best powder to compare for the treatment of ALK+ NCSLC. But fear not, for the CROWN trial be showin' progress in keepin' the scallywags survivin' free of progression for five years! Aye, the landlubbers be studyin' this closely.
Arrr mateys, listen up ye scallywags! The latest news from the CROWN trial be showin' promising results for them landlubbers with ALK+ NCSLC. After five years of studyin', it be revealed that the progression-free survival be lookin' mighty fine for them scallywags.But wait just a minute! Some of them experts be raisin' doubts about usin' crizotinib as the comparator drug. They be wonderin' if it be the best choice for comparin' the efficacy of other treatments. Aye, there be some debate brewin' among the wise ones.
So, me hearties, it be clear that the CROWN trial be makin' waves in the medical world. The results be showin' promise for treatin' ALK+ NCSLC, but there be some doubts lingerin' in the salty air. Will crizotinib be the best choice for comparin' treatments, or be there a better option out there on the high seas of medicine?